Prostate Cancer Screening: When to Start, What Tests, and Shared Decision-Making
There is no universal consensus on the age to start prostate cancer screening. Major guidelines differ:
| Organization | Recommendation |
|---|
| USPSTF (2018) | Age 55–69: Individual decision (Grade C). Age ≥70: Against (Grade D). |
| AUA (2023) | Age 55–69: Shared decision-making. Age 40–54: Only if high risk. Age ≥70: Selective. |
| ACS (2020) | Age 50 (avg risk), 45 (high risk: Black men, family history), 40 (very high risk). Discuss pros/cons. |
| NCCN | Baseline PSA at 45–50; then risk-stratified intervals. |
High-Risk Groups
- Black men: 1.7× incidence, 2.1× mortality vs. White men; earlier onset, more aggressive.
- Family history: Father/brother with PCa → 2–3× risk; multiple relatives → higher.
- Genetic mutations: BRCA2, HOXB13, Lynch syndrome.
Screening Tests
- PSA (Prostate-Specific Antigen) blood test: Primary screen. Elevated PSA ≠ cancer (BPH, prostatitis, recent ejaculation, bike riding raise it).
- DRE (Digital Rectal Exam): Palpates posterior prostate for nodules/induration. Low sensitivity alone; adds value to PSA.
- MRI / Biomarkers (4Kscore, PHI, SelectMDx): Refine biopsy decision.
Shared Decision-Making (SDM) Is Essential
Discuss:
- Benefits: Early detection → curative treatment possible; mortality reduction (modest, ~1 death prevented per 1,000 screened over 10–15 yrs).
- Harms: False positives → unnecessary biopsies (pain, infection, bleeding); overdiagnosis (indolent cancer treated unnecessarily) → incontinence, erectile dysfunction.
- Patient values: How much does he value mortality reduction vs. avoiding harm?
Practical Approach
- Baseline PSA at 45–50 (earlier if high risk).
- If PSA <1 ng/mL → repeat every 2–4 years.
- If PSA 1–3 ng/mL → repeat every 1–2 years.
- If PSA >3 ng/mL or rising rapidly → consider MRI/biomarkers/biopsy.
- Stop screening when life expectancy <10–15 years.
Prostate Cancer - Related Articles
